Bioxytran, Inc. BIXT

BIXT Company Overview

Bioxytran, Inc. is a U.S.-based biotechnology company focused on developing carbohydrate-based therapeutics and antiviral technologies. The company operates primarily in the biopharmaceutical and life sciences sectors, with research efforts centered on glycan-based compounds intended to address viral infections, hypoxia-related conditions, and inflammatory diseases. Bioxytran has historically emphasized the development of platform technologies designed to interfere with viral entry mechanisms and improve oxygen delivery or vascular function in targeted medical applications.

The company’s principal programs have included antiviral candidates such as ProLectin-M, which has been investigated for its potential role in blocking viral attachment mechanisms associated with coronaviruses, and earlier oxygen-transport and blood substitute technologies linked to the company’s original scientific direction. Bioxytran evolved from a biotechnology research enterprise focused on carbohydrate chemistry and oxygen therapeutics into a broader platform-oriented biotech company pursuing antiviral and immunological applications. Its positioning has been based on niche glycan science expertise and intellectual property associated with carbohydrate-derived therapeutic compounds.